Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pixantrone - CTI BioPharma

Drug Profile

Pixantrone - CTI BioPharma

Alternative Names: BBR-2278; BBR-2778; Pixantrone dimaleate; Pixuvri

Latest Information Update: 04 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Vermont
  • Developer Cell Therapeutics; CTI BioPharma
  • Class Anthracyclines; Anthraquinones; Antineoplastics; Isoquinolines; Small molecules
  • Mechanism of Action Alkylating agents; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Cancer
  • Discontinued Breast cancer; Myasthenia gravis

Most Recent Events

  • 01 Dec 2018 Efficacy and adverse events data from the phase III PIX306 trial in Diffuse large B cell lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)
  • 22 Oct 2018 CTI BioPharma withdraws a phase I trial in Cancer (Monotherapy, Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA, prior to enrolment (IV) (NCT02800889)
  • 14 Sep 2018 CTI BioPharma completes a phase III trial in Follicular lymphoma and Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, England, France, Germany, Hungary, Italy, Poland, Romania, Russia, Slovakia, Spain, Ukraine, USA and United Kingdom (IV) (NCT01321541)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top